Table 2.

Time to symptom improvement in the FAST-1, −2 and −3 trials

	FAST-1			FAST-2			FAST-3 (nonlaryngeal population)
	Icatibant (n = 27)	Placebo (n = 29)	P value	Icatibant (n = 36)	Tranexamic acid (n = 38)	P value	Icatibant (n = 43)	Placebo (n = 45)	P value
Time to first symptom improvement (according to patient) (hours)	0.8 (0.5–2)	16.9 (3.2–NA)	<0.001	0.8 (0.4–1.4)	7.9 (1.1–NA)	<0.001	0.8 (0.5–1)	3.5 (1.9–5.4)	<0.001
Time to first symptom improvement (according to investigator) (hours)	1 (0.8–2)	5.7 (2–11.2)	<0.001	1.5 (0.7–3)	6.9 (4–13.8)	<0.001	0.8 (0.6–1.3)	3.4 (2.6–6)	<0.001
Time to 30% reduction in symptom severity (hours)*	2.5 (1.1–6)	4.6 (1.8–10.2)	0.14	2 (1–3.5)	12 (3.5–25.4)	<0.001	NA	NA
Time to 50% reduction in symptom severity (hours)**	2.5 (NA)	7 (NA)	0.02	2 (NA)	15 (NA)	<0.001	2 (1.5–3)	19.8 (6.1–26.3)	<0.001
Time to almost complete symptom relief (hours)	8.5 (2.5–31.5)	19.4 (10.2–55.7)	0.08	10 (2.8–23.2)	51 (12–79.5)	<0.001	8 (5–42.5)	36 (29–50.9)	0.012

Notes:

^*Primary endpoint in FAST-1 and −2 studies;

^**primary endpoint in FAST-3 study. Values are expressed as median (interquartile range).

Abbreviation: NA, not available.